Abbott secures testing green lights for symptomless COVID-19 cases, plus flu, RSV Pfizer's McPherson plant, filling COVID-19 vaccine, dinged for repeat offenses last January: report Amazon Care, Intermountain form coalition to push for CMS home care reimbursement changes Apellis stops COVID-19 program after missing mortality endpoint U.S. focus on Pfizer production could delay manufacturing of other COVID-19 vaccines, Serum Institute CEO warns COVID-19 tracker: Some Catholics resist J&J vaccine; United States' hoarding of raw materials could choke world supply NIH stops trial of Brii's COVID-19 antibodies in hospitalized patients for futility Sutter Health starts major financial review after posting $321M loss in 2020 Featured Story | By Conor Hale Abbott has secured an FDA authorization for a high-throughput laboratory test that screens for four respiratory viruses from a single swab sample: COVID-19, influenza A and B, and respiratory syncytial virus. read more |
| |
|---|
|
Top Stories By Fraiser Kansteiner Pfizer recently cited upgrades to its McPherson, Kansas plant as one of the ways it would double weekly vaccine output in the U.S. by mid-March. But that plant has endured an onslaught of FDA complaints since Pfizer acquired it in its 2015 Hospira buyout, with inspectors citing offenses as recently as last January. read more By Heather Landi Home-based care companies, including Amazon Care and two health systems, are lobbying Congress to make permanent changes to home health care reimbursement policies. Intermountain Healthcare and Ascension are two of the founding members of the Moving Health Home coalition to change the way policymakers think about the home as a site of clinical service. read more By Nick Paul Taylor Apellis Pharmaceuticals has stopped development of APL-9 in severe COVID-19 patients after an interim review of phase 1/2 mortality data. The review found adding the C3 therapy to standard of care had no meaningful effect on mortality, prompting Apellis to pull the plug on the program. read more By Fraiser Kansteiner As the U.S. locks up supplies to make Pfizer's COVID-19 vaccine, Serum Institute of India and WHO are raising flags about global supply bottlenecks and raw materials shortfalls, Bloomberg reports. The supply disruption comes after the Biden Administration tapped the Defense Production Act to increase deliveries of Pfizer's shot in the U.S. read more By Kevin Dunleavy,Fraiser Kansteiner,Eric Sagonowsky,Angus Liu,Conor Hale There is debate within the Catholic Church over the morality of taking the Johnson & Johnson COVID-19 vaccine, cell lines for which were initially developed with aborted fetuses. The U.S. reserving materials for Pfizer's COVID-19 vaccine production could lead to supply bottlenecks around the world. read more By Nick Paul Taylor The NIH has halted a clinical assessment of two Brii Biosciences antibodies in hospitalized COVID-19 patients for futility. Brii’s BRII-196 and BRII-198 became the latest anti-SARS-CoV-2 antibodies to fail to improve outcomes in hospitalized individuals but remain in development in ambulatory patients. read more By Robert King Sutter Health posted a $321 million loss for 2020, which triggered a massive review of which operations and services it should wind down. read more |
